Candel Therapeutics is advancing its immunotherapy using HSV gene constructs, with clinical trials underway under FDA agreement.

The entities involved

• FDA →
  • Generic medicine services are seeking approval for launch from the FDA.Mon 17:49
  • A company is seeking FDA feedback on its NEO212 program, with a meeting scheduled at the FDA's White Oak campus.Mon 14:56
• Candel Therapeutics →

  company in Auburndale, United States

  Nothing else this week.

• Boston →

  capital and largest city of Massachusetts, United States

  • The Federal Aviation Administration is managing air traffic operations at Boston Logan Airport.Mon 17:34
  • Modulate leverages benchmarks set by Hugging Face.Mon 17:24

Related events

• Solid Biosciences received FDA approval for a gene therapy trial on July 9, 2025.Jun 8
• FDA placed a clinical hold on a gene therapy involving Hunter.Aug 25
• Pfizer and Valneva are partnering on a Lyme vaccine and are currently seeking necessary approval from the FDA.Aug 29
• Capricor Therapeutics is seeking regulatory approval from the FDA for clinical trials and has listed on the Nasdaq stock exchange, with a law firm based in New York City involved.Aug 5
• Immuneering submitted a meeting request to the FDA regarding its therapies.Jun 7